A pilot study of patients with oligometastases from breast cancer treated with stereotactic ablative body radiosurgery.
- Conditions
- Metastatic Breast Cancer (oligometastatic 1-3 bone metastases)Cancer - BreastCancer - Bone
- Registration Number
- ACTRN12614000484640
- Lead Sponsor
- Peter MacCallum Cancer Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
* Aged > 18 years.
* Has provided signed written informed consent for participation in this trial.
* Histological or cytologically confirmed breast cancer.
* Primary breast cancer controlled.
* Whole Body Bone Scan (WBBS), CT Scan (Chest, Abdo + Pelvis) and Na-18F PET Scan evidence of 1 to 3 active metastases (bone only) within 8 weeks of study registration.
* An ECOG performance status score of 2 or less.
* Life expectancy greater than 12 months.
* Willing and able to comply with all study requirements, including treatment, attending required assessments and follow-up.
* Previous high dose radiotherapy (BED > 20Gy) to an area to be treated which includes vertebral bodies
* Visceral Metastases (e.g. liver, lung or brain)
* Treatment with any chemotherapy agent within +/- 3 weeks of SABR
* Evidence of Spinal Cord Compression.
* Spinal Instability Neoplastic Score greater than or equal 7 unless lesion reviewed by a neurosurgical service and considered stable. A dose of 28Gy in 2 fractions can be considered after review at SABR chart round.
* Surgical fixation of lesion required for stability.
* Lesion in a long bone (femur or humerus) which involves the cortex.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method